PATENT CLAIM ANALYSIS

Application Number: 16029352
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-12
Patent Classification: ["424", "174100"]

Abstract:
The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy.

Claim (Index 16):
The method of  claim 1 , wherein said immunotherapeutic is of an amount that is capable of:\n (1) inducing IFN-\u03b1 in an enriched human blood DCs; (2) inducing TNF-\u03b1 in an enriched human blood DCs; (3) inducing IL-12-\u03b1 in an enriched human blood DCs; (4) activating CD45+ immune cells in tumor microenvironment; (5) activating CD4+ and CD8+ T cells in tumor microenvironment; (6) activating NK cells in tumor microenvironment; (7) activating plasmacytoid dendritic cells (pDC) and myeloid dendritic cells (mDc) in tumor microenvironment; (8) activating macrophages and Monocytes in tumor microenvironment; and/or (9) increasing migratory DCs in draining lymph nodes.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 95.0
- Lexical Diversity: 1.0
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15110685', '15793820', '15110690', '15849436', '15849470']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7721191375239529
- 35 USC 102 Novelty (BERT): 0.5369452883053611
- Combined Prediction Score: 0.7486017526020938
- Mean Citation Score: 337.588756
- Max Citation Score: 377.97064
- Similarity Product: 286.4138889054775

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test